Listed

BriaCell Therapeutics Corp.: Form 10-Q for the period ended Oct 31, 2022

Filed with the SEC on Dec 14, 2022 and accepted by EDGAR at Dec 14, 2022, 16:44 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2022-10-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Research and development3 months2022-08-01 to 2022-10-31$3.3mus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2022-08-01 to 2022-10-31−$5.4mus-gaap:OperatingIncomeLoss
Net income3 months2022-08-01 to 2022-10-31−$1.1mus-gaap:NetIncomeLoss
Basic EPS3 months2022-08-01 to 2022-10-31−$0.07us-gaap:EarningsPerShareBasic
Operating cash flow3 months2022-08-01 to 2022-10-31−$3.5mus-gaap:NetCashProvidedByUsedInOperatingActivities
Cash and equivalentsAt period end2022-10-31$37.5mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2022-10-31$38.2mus-gaap:AssetsCurrent
Total assetsAt period end2022-10-31$38.5mus-gaap:Assets
Current liabilitiesAt period end2022-10-31$974.0kus-gaap:LiabilitiesCurrent
Shareholders' equityAt period end2022-10-31$10.3mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001493152-22-035452. Last ingested by Listed: Oct 24, 2026, 15:07 ET. Listed shows no prices and gives no investment advice.